Physicians' Academy for Cardiovascular Education

IL-6 as therapeutic target in inflammation and CVD

10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD - Boston, MA, USA

Video navigation menu

  • CRP levels predict CV events 00:39
  • The CANTOS trial 03:30
  • Findings of studies on IL-6 and CV risk 06:08
  • Ziltivekimab and the ZEUS trial 08:28
  • Summary 12:46


Show transcript

Educational information

This presentation by Paul Ridker is part of a series titled "Inflammation: The next therapeutic frontier in targeting cardiovascular risk". This series consists of an introduction, three lectures and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.


Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Novo Nordisk.A/S


This educational activity is intended for an international audience of non-US and non-UK HCPs

Listen to the podcast View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: